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Toll-like receptor (TLR) signaling is a key component
of innate immunity. Aberrant TLR activation leads to
immune disorders via dysregulation of cytokine pro-
duction, such as IL-12/IL-23. Herein, we identify and
characterize PIKfyve, a lipid kinase, as a critical
player in TLR signaling using apilimod as an affinity
tool. Apilimod is a potent small molecular inhibitor
of IL-12/IL-23 with an unknown target and has been
evaluated in clinical trials for patients with Crohn’s
disease or rheumatoid arthritis. Using a chemical
genetic approach, we show that it binds to PIKfyve
and blocks its phosphotransferase activity, leading
to selective inhibition of IL-12/IL-23p40. Pharmaco-
logical or genetic inactivation of PIKfyve is necessary
and sufficient for suppression of IL-12/IL-23p40
expression. Thus, we have uncovered a phosphoino-
sitide-mediated regulatory mechanism that controls
TLR signaling.
INTRODUCTION
Toll-like receptors (TLRs) recognize molecules that are broadly
shared by pathogens yet are distinguishable from host mole-
cules. Activation of TLR signaling induces expression of genes
that orchestrate the inflammatory and antipathogen responses
(Takeuchi and Akira, 2010). It is known that dysregulated TLR
signaling plays a role in a number of autoimmune diseases pri-
marily due to dysregulation of cytokine production (Krieg and
Vollmer, 2007). IL-12 and IL-23 are cytokines of particular
importance: they share the common IL-12p40 subunit and are
key drivers for the development of T helper cell-type 1 (Th1)
and -type 17 (Th17) cells, respectively (Langrish et al., 2004).912 Chemistry & Biology 20, 912–921, July 25, 2013 ª2013 Elsevier LBoth cytokines are clinical targets for the treatment of autoim-
mune disease (Abraham and Cho, 2009; Gately et al., 1998).
The activation of these cytokines is under tight control by
the TLR signaling network, including NFkB, IRF, MAPK, and
PI3K pathways. In addition to these signaling pathways, many
positive or negative regulators have also been recently discov-
ered to play important roles in TLR-cytokine expression. Clas-
sical genetics has played a central role in the discovery of
many key regulators in TLR biology. A number of critical nodes
were successfully identified by forward genetics. For example,
UNC93B, a key chaperone for endosomal TLRs, was identified
fromanN-ethyl-N-nitrosourea (ENU)mutagenesis-based screen
(Tabeta et al., 2006). Hypothesis-driven reverse genetics has
become a dominant approach over the past 10–15 years in
elucidating TLR signaling network using specific gene deletion
or mutation approaches (Medzhitov et al., 1997; Yamamoto
et al., 2003).
In addition to these classical gene discovery approaches, for-
ward chemical genetics has emerged as another powerful
approach to illuminate the biological function of genes, particu-
larly in the case where a gene is a multifunctional enzyme, or
its deletion/mutation leads to embryonic lethality. This is
achieved by identifying the target of a small molecular com-
pound that induces a phenotype of interest (Schreiber, 2000;
Spring, 2005; Kung and Shokat, 2005). A number of proteins
that govern fundamental cellular processes have been charac-
terized using small molecular drugs. For example, the molecular
target and mechanism of action for rapamycin, a widely used
immunosuppressant during organ and bone marrow transplan-
tation, were elucidated by forward chemical genetics (Sabatini
et al., 1994; Kunz et al., 1993; Brown et al., 1994; Chiu et al.,
1994). Rapamycin interacts with the FKBP-rapamycin-binding
(FRB) domain of the mammalian target of rapamycin (mTOR)
and inhibits its kinase activity within mTORC1 complex (contain-
ingmTOR, Raptor, andmLST8) during acute administration. This
discovery led to an explosion of studies revealing important roles
of mTOR in multiple biological processes using rapamycin as antd All rights reserved
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Apilimod Is a Highly Selective PIKfyve Inhibitorinhibitor, including its function in TLR9-induced IFNa production
(Cao et al., 2008). However, the limitation of available potent
small molecules that perturb interesting biological pathways
has posed challenges in fully utilizing the potential of chemical
genetics. Although there are very few disease-modifying com-
pounds targeting the TLR-cytokine axis (Hennessy et al.,
2010), apilimod emerges as an ideal tool for additional gene dis-
covery in TLR signaling.
Apilimod is a small molecule compound developed to specif-
ically block TLR-mediated IL-12/IL-23 production that has
entered clinical trials (Wada et al., 2007, 2012). It has been tested
in patients with Crohn’s disease (CD), rheumatoid arthritis (RA)
(Billich, 2007), and psoriasis (Wada et al., 2012). Although apili-
mod showed clinical improvement in patients with active CD in
a phase I/IIA trial, no significant improvement over placebo
was seen in a phase II trial (Sands et al., 2010; Burakoff et al.,
2006), though it was generally well tolerated. At the onset of
these trials, the therapeutic target(s) for apilimod was unknown,
making the assessment of efficacy and toxicity difficult due to a
lack of appropriate pharmacodynamic (PD) markers. Without
knowledge of the target, further progress in the development
or improvement of this drug is challenging.
In this study, using apilimod as an affinity probe, we found
phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) to be the
molecular target of this drug. PIKfyve is a 240 kDa lipid kinase
that phosphorylates the D-5 position in endosomal phosphatidy-
linositol-3-phosphate (PI3P) to yield the 3,5-bisphosphate
(PI(3,5)P2) (Shisheva, 2008). This kinase binds to PI(3)P via its
FYVE domain. PIKfyve is critical for maintaining the proper
morphology of the endosome/lysosome. The enlarged endo-
some/lysosome structure was observed in cells expressing
PIKfyve dominant negative or siRNA (Ikonomov et al., 2001;
Rutherford et al., 2006). Vac14 and Sac3 were reported to form
a regulatory complex with PIKfyve to control the endosomal
phosphoinositide metabolism (Sbrissa et al., 2004, 2007). The
vacuolization and low PI(3,5)P2 levels in fibroblasts isolated
from Vac14 and Sac3 null mice suggest that both are required
for maximal PIKfyve activity (Jin et al., 2008; Zhang et al.,
2007; Chow et al., 2007). PIKfyve-mediated PI(3,5)P2 signaling
was reported to regulate endosomal trafficking and play a key
role in multiple biological processes, such as GLUT4 transloca-
tion and retroviral budding (Ikonomov et al., 2002; Jefferies
et al., 2008). Neurodegeneration was observed in both humans
and mice with Vac14 and Sac3 mutations (Zhang et al., 2007;
Chow et al., 2007; Jin et al., 2008), possibly due to the deficiency
of autophagy-mediated intracellular trafficking in cells lacking
PI(3,5)P2 (Ferguson et al., 2009). Here, we report that apilimod
specifically binds to PIKfyve and inhibits its lipid kinase activity
and demonstrate PIKfyve’s function in controlling TLR-mediated
cytokine expression. These findings unravel the critical role of
PI(3,5)P2 in modulating TLR signaling and control of discrete
immune cell functions.
RESULTS
Apilimod Selectively Inhibits TLR-Induced Cytokine
Expression
Apilimod is a 1,3,5-triazine derivative discovered in a cell-based
screen aimed at identifying inhibitors of IL-12 production, usingChemistry & Biology 20,IFNg/LPS-stimulated human peripheral bloodmononuclear cells
(PBMCs) (Wada et al., 2007). We found that in addition to this
TLR4-dependent pathway, apilimod inhibited the expression of
IL12p40 induced by other TLRs (Figure 1A; Figure S1 available
online). TLR ligand/agonist pairs used are LPS (TLR4), ssRNA
(TLR7), R837 (TLR7), and R848 (TLR7/8). This inhibitor thus
regulates the expression of IL-12 induced by multiple TLRs.
Consistent with the results in human PBMCs (Wada et al.,
2007), apilimod selectively inhibited the production of IL12p40,
whereas it had little effect on IL8 production in THP-1 cells (Fig-
ure 1B). Apilimod thus exhibited potent yet selective cellular
activity in TLR pathways. In addition, we also evaluated the
activity of apilimod in mouse cells. As shown in Figure 1C, apili-
mod selectively inhibited IFNg/LPS or R848-induced production
of IL12p40 but not CXCL2 in mouse bone marrow-derived den-
dritic cells (BMDCs). Apilimod thus exhibited selective cellular
activity across multiple species. It would therefore be important
to identify themolecular target(s) for apilimod and reveal a poten-
tial novel regulatory mechanism for TLR cytokine modulation.
Apilimod Binds to and Inhibits PIKfyve Kinase Activity
First, we aimed to identify the binding partners of apilimod to
yield potential molecular target(s) by employing a quantitative
chemical proteomics approach (Huang et al., 2009). A bioactive
analog of apilimod, APA10 (Figure 2A), was immobilized on a gel
matrix and incubated with a THP-1 cell extract premixed with
either DMSO or with an excess of apilimod. Unbound proteins
were removed by washing, and specifically bound proteins
were eluted, digested, and identified using LC-MS/MS. Although
a total of 974 retained proteins were identified (Table S1), only 3
proteins were significantly competed from the matrix by
increasing dose of apilimod. The three proteins identified
comprise all knownmembers of the PIKfyve regulatory complex:
PIKfyve, Vac14, and Sac3 (Figure 2B). In an independent pull-
down experiment, PIKfyve protein was competed from the
matrix with apilimod, but not with an inactive analog API09 (Fig-
ures 2A and 2C). Vac14 and Sac3 form a complex with PIKfyve,
and both are required for maintaining PIKfyve activity in convert-
ing PI3P to PI(3,5)P2. We conclude that apilimod specifically in-
teracts with the PIKfyve regulatory complex in cells.
To address the mode of action of apilimod on the PIKfyve
complex, an in vitro kinase assay measuring the conversion of
PI(3)P to PI(3,5)P2 was developed. Apilimod inhibited PIKfyve
kinase activity with an IC50 of 14 nM (Figure 2D). In contrast, api-
limod had no activity toward other lipid kinases and protein
kinases, including PIP4K, PIP5K, mTOR, PI3K, and PI4K iso-
forms (Figure 2E; Table S2). In addition, we mapped the
apilimod-binding region to the PIKfyve kinase domain (amino
acids 1,522–2,098, Figure 2F). Furthermore, in a competition
assay using fluorescence polarization of a labeled apilimod
analog (Cy5-apilimod), unlabeled apilimod showed an IC50 of
12 nM, indicating that this interaction is responsible for the
inhibition of the catalytic activity described above (Figures 2G
and 2H). These results demonstrated that apilimod is a potent
yet highly selective PIKfyve lipid kinase inhibitor.
Apilimod Inhibits PIKfyve Kinase Activity in Cells
To determine if apilimod affected PIKfyve function in cells, we
quantified cellular phosphoinositides upon apilimod treatment.912–921, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 913
Figure 1. Apilimod Selectively Inhibits TLR-Induced Cytokine Expression
The production of cytokines was measured by ELISA following overnight stimulation. Representative results were shown from three independent experiments.
(A) Inhibition of IL12p40 by apilimod following stimulation of cells with IFNg (50 ng/ml)/LPS (1 mg/ml), R837 (10 mg/ml) and R848 (10 mg/ml), or ssRNA (ORN 02,
5 mg/ml) (see also Figure S1).
(B) THP-1 cells were treated with apilimod in the presence of IFNg (50 ng/ml)/LPS (1 mg/ml). The data were analyzed using one-way ANOVAmethod (p < 0.0001),
indicating a significant effect of apilimod on TLR4-induced expression of IL12p40.
(C)Mouse BMDCswere treatedwith apilimod (1 mM) and challengedwith IFNg (50 ng/ml)/LPS (1 mg/ml) or R848 (0.1 mM). **p < 0.01 using the Student’s t test. Data
represent mean values ± SD.
Error bars represent SD.
See also Figure S1.
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(HPLC) analysis of deacylated lipids revealed a specific dose-
dependent decrease of PI(3,5)P2 in HeLa cells treated with apili-
mod but not with the inactive analog API09 for 2 hr. Additionally,
a marked increase (up to 2.5-fold) of PI(3)P was observed, which
clearly demonstrated that apilimod inhibited PIKfyve activity in
cells and blocked the conversion of PI(3)P to PI(3,5)P2. Strikingly,
even a low-dose treatment of apilimod (10 nM) resulted in a
marked decrease of cellular PI(3,5)P2 levels. In contrast, all other
phosphoinositides tested were largely unchanged even when
cells were treated with 1 mM apilimod. These observations are
consistent with apilimod being a highly selective and potent in-
hibitor of PIKfyve (Figures 2D and 2E).
Because PIKfyve is reported to be critical for maintaining the
integrity of endosomes and lysosomes (Dove et al., 2009), we
then examined cell morphology. Upon treatment with apilimod,
we observed enlarged vacuoles in RAW264.7 cells (Figures 3B
and 3C), which were also seen upon inactivation of PIKfyve using
a dominant-negative PIKfyve mutant or RNAi (Ikonomov et al.,
2001; Rutherford et al., 2006). In contrast, treatment with
API09 did not induce vacuoles (Figure 3B). Using an early endo-914 Chemistry & Biology 20, 912–921, July 25, 2013 ª2013 Elsevier Lsome (GFP-FYVE) or an endolysosome (mCherry-CD63) marker,
we showed that the enlarged vacuoles originate from both early
endosome and endolysosome, which is consistent with the find-
ings in PIKfyve-deficient cells (Rutherford et al., 2006) (Figure 3D).
Hence, the vacuoles induced by apilimod are due to the disrup-
tion of PIKfyve activity. Indeed, overexpression of wild-type (WT)
GFP-PIKfyve caused the disappearance of vacuoles induced by
10 nM apilimod in A549 cells, whereas overexpression of the
dominant-negative GFP-PIKfyve-K1831E ‘‘kinase dead’’ mutant
caused more extensive vacuole formation (Figure 3E). These
data are fully consistent with PIKfyve being the cellular target
of apilimod.
PIKfyve Modulates TLR-Induced IL-12p40 Expression
To establish a functional correlation between PIKfyve and TLR-
cytokine production, we first analyzed THP-1 cells infected
with PIKfyve shRNAs. As shown in Figures 4A and 4B, knock-
down of PIKfyve in THP-1 cells led to decreased production of
IL-12p40, whereas it had little effect on IL8 production. This is
consistent with the cytokine profile observed in apilimod-treated
cells (Figure 1B).td All rights reserved
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PIKfyve activity were also defective in TLR signaling. Because
PIKfyve knockout mice are embryonic lethal (Ikonomov et al.,
2011), we utilized the spontaneous mutant mouse, ingls, which
carries a missense mutation in Vac14 (L156R) (Jin et al., 2008).
ingls mutation interrupts the interaction of PIKfyve with Vac14,
which abolishes the kinase activity of PIKfyve and reduces the
level of PI(3,5)P2, a phenotype closely mimicking that seen
during PIKfyve inhibitor application. Indeed, BMDCs from
Vac14ingls/ingls mice exhibited profound vacuole formation as
seen in apilimod-treated BMDCs from WT mice (Figure 4C). As
shown in Figure 4D, production of IL12p40 but not CXCL2 was
impaired in CD11c+ BMDCs derived from Vac14ingls/ingls bone
marrow upon treatment with IFNg/LPS or R848. These data
are consistent with the cytokine-profiling patterns observed in
cells treated with apilimod (Figure 1C). Taken together, our
data suggest that PIKfyve is the molecular target of apilimod,
revealing a link between PIKfyve and cytokine expression
induced by TLR signaling.
DISCUSSION
In this study, we characterized an important regulator of
TLR signaling through identification of the target of a small mole-
cule compound. The results uncovered a mechanism for selec-
tive regulation of TLR-driven cytokine expression mediated by
localized control of minor species of phosphoinositides in
cells. By characterizing a selective TLR-cytokine inhibitor, our
study has illustrated the power of chemical genetic approaches
in providing insights into TLR signaling. Although a PIKfyve inhib-
itor YM201636 has been described previously (Jefferies et al.,
2008), it is a weaker PIKfyve inhibitor that possesses activity
toward PI3K family members (Jefferies et al., 2008; Ikonomov
et al., 2009). Therefore, apilimod is a more desirable tool to be
used in elucidating the role of PIKfyve in important biological
processes.
Using high-content screen and cell-based high-throughput
function screen technology, a number of small molecular
agonists or antagonists for specific phenotypic changes have
been identified. Although the drug discovery pipeline is
greatly expanded with the discovery of these compounds, the
absence of efficacy target(s) and of a mechanism of action of
these leads hindered the progress of pipeline development,
such as compound optimization and safety evaluation. A
practicable drug target ‘‘fishing’’ strategy is desperately
needed to hunt for the ‘‘prey’’ of these compounds. Recently,
chemoproteomics has been shown to be a powerful tool to
address this issue (Huang et al., 2009). Our studies provided
a successful case of chemoproteomics-driven target iden-
tification. The PIKfyve regulatory complex was the only pro-
teins competed off from the affinity matrix in the presence of
active analog among the 974 proteins quantified from total
cell lysate using LC-MS/MS. This is the key step for iden-
tifying the binding partner of apilimod and enabled a rapid
target validation. Moreover, this approach could provide a rapid
and exhaustive method to predict the specificity of a
compound. As in this case, apilimod was later shown to have
no activity toward other protein and lipid kinases (Figure 2E;
Table S2).Chemistry & Biology 20,The target elucidation of apilimod provides a number of
benefits for drug development. First, a PIKfyve activity-based
biochemical screen could be performed to find other inhibitors.
Second, the safety issues, particularly ‘‘on-target’’ versus ‘‘off-
target’’ effects of compound, could bemonitored and addressed
during the development. More importantly, the target identifica-
tion provides an opportunity to shed light on the molecular
mechanism of PIKfyve inhibition-mediated TLR signaling defect.
This not only expands the therapeutic indications for apilimod
but also enables the expansion of the PIKfyve network down-
stream of TLR signaling to reveal more druggable nodes that
could potentially bypass the on-target toxicity induced by
PIKfyve inhibition.
It is well established that inositol phospholipids play a critical
role in intracellular signaling, and several of these specifically
regulate TLR pathways. For example, Kagan and Medzhitov
proposed that PI(4,5)P2-mediated TIRAP recruitment to the
plasma membrane is required for the delivery of MyD88 to
TLR4 (Kagan and Medzhitov, 2006). Also, class I PI3K inhibitors
abolish endosomal TLR-induced type I IFN production in pDC
by blocking nuclear translocation of IRF7, but not the uptake
and endosomal trafficking of ligands (Guiducci et al., 2008).
In contrast, PI3K could function as a negative regulator for
TLR-induced IL-12 synthesis in DCs and THP-1 cells (Fukao
et al., 2002). Here, we show that a mammalian PI kinase,
PIKfyve, regulates TLR signaling via modulation of PI(3)P and
PI(3,5)P2 levels. Interestingly, PI(3)P and PI(3,5)P2 are two of
the least-abundant phosphoinositide species in cells (0.25%
of cellular inositol lipids) yet are critical for the maintenance of
a normal endosomal compartment. Their critical role becomes
clear in the presence of PIKfyve inhibitors: where treated cells
form large vacuoles of endosomal/lysosomal origin (Figure 3D).
It remains to be seen how PIKfyve-dependent modulation of
endosomal PI(3)P and PI(3,5)P2 levels regulates specific TLR-
cytokine expression. Because the PIKfyve kinase knockin
mice are embryonic lethal (data not shown), apilimod will
become an important tool to dissect the function of PIKfyve
lipid kinase activity in TLR pathways as well as other biological
processes.
In summary, we uncovered a role of PIKfyve in selectively
regulating TLR signaling. Our results thus propose an additional
druggable node for selective regulation of TLR-induced IL-12/
IL-23 expression and, in turn, provide opportunities for pharma-
cological intervention in IL-12/IL-23-mediated diseases.
SIGNIFICANCE
Selective low molecular weight inhibitors of aberrant cyto-
kine expression are a highly desirable therapy to treat
autoimmune disorders (Dinarello, 2010). Although several
small molecule signaling modulators are under investiga-
tion, such as p38 and IKKb inhibitors, there are very few
disease-modifying compounds that target the TLR-
cytokine axis and none of which that has a known mech-
anism of action (Hennessy et al., 2010). Our results un-
cover the molecular and therapeutic target of a clinically
evaluated anti-inflammation drug that inhibits TLR-driven
IL-12/IL-23 production. This report demonstrates a role
for PIKfyve in TLR signaling and illustrates the power of912–921, July 25, 2013 ª2013 Elsevier Ltd All rights reserved 915
Figure 2. Apilimod Binds to and Inhibits PIKfyve Kinase Activity
(A) Structure of apilimod, its analogs, and IC50 values for IFNg (50 ng/ml)/LPS (1 mg/ml)-induced IL-12p40 secretion in THP-1 cells.
(B) Scatterplot depicting proteins identified in a quantitative chemical proteomics experiment. Proteins are plotted as a function of the percent competition with
apilimod relative to DMSO, on the y axis, versus the interaction specificity (e value) on the x axis (see also Table S1 for protein list for apilimod quantitative
chemical proteomics).
(C) U2OS cell lysates were preincubated with DMSO or indicated competitor compound for 30 min before adding beads with immobilized APA10. The PIKfyve
captured on the beads was detected by western blot.
(legend continued on next page)
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Figure 3. Apilimod Inhibits PIKfyve Kinase Activity in Cells
(A) HeLa cells metabolically labeled with [3H]inositol for 72 hr and treated with two doses of apilimod or the inactive analog API09 for 120 min. Lipids were
extracted, deacetylated, and analyzed by HPLC. Data were normalized with cells treated with DMSO vehicle control and analyzed using the Student’s t test (*p <
0.05, **p < 0.01), showing a significant difference of the indicated phosphoinositide levels between API09 and apilimod-treated samples. Error bars represent SD.
(B) Images of RAW264.7 cells treated with DMSO, apilimod (10 nM), or API09 (10 nM) for 3 hr. The results are representative from three independent experiments.
(C) Electron microscope images of RAW264.7 cells treated with apilimod (200 nM) for 6 hr.
(D) RAW264.7 cells stably expressing GFP-FYVE (early endosome marker) or mCherry-CD63 (endolysosome marker) were treated with DMSO or apilimod
(100 nM) for 60 min. Images were acquired using a Zeiss LSM510 confocal microscope with 633 lens. Scale bar, 5 mm.
(E) A549 cells transfected with GFP-PIKfyve (mouse) or GFP-PIKfyve K1831Emutant (mouse) were treated with 10 nM apilimod for 4 hr and imaged using a Zeiss
Axiovert microscope. Arrows indicate GFP-positive cells. The results are representative from three independent experiments.
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Apilimod Is a Highly Selective PIKfyve Inhibitorchemical genetic approaches. The identification of PIKfyve
as the molecular target of apilimod yields an additional
signaling node within the TLR signaling cascade that
could be targeted in inflammatory conditions and allows
the optimization of the compound for further development.(D) The effect of apilimod on human PIKfyve kinase activity was measured in vitr
(E) Lipid kinase inhibition profiling for apilimod (see also Table S2 for protein kina
(F) The binding of apilimod with indicated human PIKfyve truncants was assesse
(G) The KD of Cy5-apilimod to PIKfyve kinase domain was determined.
(H) The IC50 of apilimod for the interaction between Cy5-apilimod and PIKfyve ki
See also Table S2.
Chemistry & Biology 20,More importantly, we demonstrate that apilimod is a
potent and highly selective PIKfyve inhibitor and provide
the scientific community with a powerful tool to eluci-
date the role of PIKfyve kinase activity in multiple cellular
processes, including endolysosomal integrity, receptoro by quantifying the ratio of synthesized PI(3,5)P2 to an internal standard.
se inhibition profiling for apilimod).
d using a APA10-based Sepharose HP affinity resin.
nase domain was determined. Error bars represent SD.
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Figure 4. PIKfyve Modulates TLR-Induced IL12p40 Expression
(A) THP-1 cells expressing indicated shRNAs were lysed and blotted with indicated antibodies.
(B) THP-1 cells expressing indicated shRNAs were stimulated with IFNg (50 ng/ml)/LPS (1 mg/ml) overnight. The cytokine production was measured by ELISA.
**p < 0.01 using the Student’s t test indicating a significant difference on IL12p40 production between cells expressing control (NT) and PIKfyve shRNA.
(C) Images of BMDCs from WT and ingls mice and those from WT BMDCs treated with DMSO or apilimod (1 mM).
(D) BMDCs from WT or ingls mice were challenged with IFNg (50 ng/ml)/LPS (1 mg/ml) or R848 (0.1 mM). The cytokine production was measured by ELISA
following overnight stimulation. Representative results are from three independent experiments. **p < 0.01 using the Student’s t test indicating a significant
difference between the samples from WT and ingls mice with the same treatment.
Error bars represent SD.
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Apilimod Is a Highly Selective PIKfyve Inhibitortrafficking, autophagy, and neurodegeneration among
others.EXPERIMENTAL PROCEDURES
Constructs and Reagents
The lentivirus mCherry-CD63 was made as previously described by Kim
et al. (2008). pENTR-PIKfyve (mouse) was purchased from Invitrogen.
pENTR-PIKfyve K1831E was created using QuikChange XL Site-Directed918 Chemistry & Biology 20, 912–921, July 25, 2013 ª2013 Elsevier LMutagenesis Kit (Stratagene). pENTR-PIKfyve (human) was purchased from
GeneCopoeia. The PIKfyve WT and kinase-dead mutant were subcloned
into pcDNA6.2/N-EmGFP-DEST vector (Invitrogen) using LR clonase.
All the control and gene-specific shRNAs used in the experiments were
ordered from the Sigma-Aldrich MISSION shRNA collection. The control NT
shRNA is the pLKO.1-puro nonmammalian shRNA control. This control con-
tains a shRNA insert that does not target human and mouse genes.
PIKfyve antibody was purchased from Abnova. Tubulin antibody was
purchased from Abcam. All TLR ligands were purchased from InvivoGen. All
ELISA kits were obtained from R&D Systems.td All rights reserved
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THP-1, U2OS, RAW264.7, and A549 cells were purchased from ATCC and
maintained under standard conditions described in the ATCC instructions.
Human PBMCs were isolated using Ficoll (GE Healthcare). The isolation and
in vitro differentiation of mouse bone marrow cells were performed as previ-
ously described by Gilliet et al. (2002). Cell differentiation was confirmed by
CD11c staining.
Compound Affinity Pull-Down and Mass Spectrometry Analysis
Compound affinity purification, mass spectrometry, and data analysis were
performed essentially as previously described (Huang et al., 2009), except
that the cell lysate was made from THP-1 cells, and apilimod bioactive
analog APA10 was coupled to NHS (N-hydroxysuccinimide)-activated
Sepharose 4 beads. The e value on x axis indicates the frequency of each
protein that was detected in prior proteomics experiments. Small e values
are considered advantageous because this suggests a specific protein
interaction.
Expression of Human PIKfyve
HEK293T cells were seeded in 6-well plates at a density of 5 3 105 cells per
well in DMEM containing 10% FCS. After 24 hr, when a confluency of about
50% had been reached, the cells were transfected with an expression plasmid
encoding human PIKfyve as a fusion protein with GST. Transfection was done
using FuGENE (Roche; 3 ml per well) and 1 mg/well of the DNA. Forty-eight
hours after the transfections, cells were washed with ice-cold PBS and then
scraped into 0.5 ml ice-cold lysis buffer (50 mM HEPES [pH 7.5], 150 mM
NaCl, 1 mM EDTA, 1% Nonidet P-40, 10 mM b-glycerophosphate, protease
inhibitor [Roche]). Following centrifugation, the supernatant was harvested,
followed by addition of glutathione Sepharose beads (GE Healthcare; equili-
brated with lysis buffer; approximately 100 ml of packed beads/ml of lysate).
After 1 hr incubation with end-over-end agitation, the beads were washed
three times with lysis buffer with 1% Nonidet P-40, then three times with lysis
buffer without NP40. Beads were collected by centrifugation at 500 3 g and
used directly in the enzyme assay.
In Vitro Kinase Assay
A total of 5 ml of the compound or its dilution series in the assay buffer
(25 mM HEPES buffer, 1 mM DTT, 5 mM glycerophosphate, 2.5 mM
MgCl2, 2.5 mM MnCl2, 120 mM NaCl, 1 mM EDTA), 10 ml of human PIKfyve
enzyme purified from HEK293 cell lysates, and 5 ml 50 mM ATP solution
were preincubated for 5 min at the room temperature. Then, 5 ml of the di-
C8 PI(3)P substrate (Echelon Biosciences) was added into the wells to
have the final concentration of the substrate at 10 mM to initiate the reaction.
The reactions were allowed to proceed at room temperature for 2 hr and then
quenched by adding 25 ml acetonitrile/water (50:50 v/v) solution, which also
contained 25 mM EDTA and 1 mM di-C8-sPI(3,4)P2 (internal standard;
Cayman Chemical). After centrifugation, the plate was sealed for LC-MS/
MS analysis. The MS/MS data were acquired on a Thermo TSQ triple-
quadruple MS system (Thermo Fisher Scientific) coupled to a Thermo LX2
HPLC system. The LC system was run in the reverse-phase chromatography
mode using a Waters XBridge C18 column (2.1 3 30 mm, 3.5 mm). The LC
mobile phase contained 0.1% dimethylisopropylamine (DMIPA) in either
water (mobile A) or acetonitrile (mobile B). The flow rate was 0.8 ml/min
with a rapid gradient from 5% to 95% B in 1.2 min. The injection volume
was 5 ml. The MS/MS transition for PI(3,5)P2 was 745.06 / 158.98 with
23 eV as collision energy, whereas the transition for internal standards was
761.06/ 158.98.
All other kinase assays were performed internally by Novartis kinase-
profiling service except for assays for PIP4K and PIP5K. The effect of apilimod
on PIP4K and PIP5K isoforms was determined by Millipore IC50 Profiler
Service.
Measurement of Cellular Inositol Lipid Levels
HeLa cells were incubated for 72 hr in inositol-free DMEM (MP Biomedicals)
supplemented with 10% dialyzed FBS (Invitrogen) and 25 mCi/ml 3H-myo
inositol (MP Biomedicals). Compounds were then added to the cells and incu-
bated for 120 min. Prior to lipid extraction, cells were washed twice with PBS
and incubated 15 min in inositol-free DMEM supplemented with 10% dialyzedChemistry & Biology 20,FBS and compounds. Cells were then treated with 0.7 ml 4.5% perchloric
acid in ice for 15 min, scraped, and centrifuged. Pellets were washed
twice with ice-cold 1 ml 0.1 M EDTA and deacylated as described by Kirk
et al. (1990). Deacylated phosphoinositides were separated using HPLC
(Shimadzu) using a flow rate of 0.5 ml/min and a gradient of degassed H20
(pump A) and 1 M (NH4)2HPHO4 (pH 3.8) (pump B) as follows: 0% B for
5 min; 0%–4% B for 15 min; 4% B for 80 min; 4%–12% B for 20 min; 12%
B for 60 min; 12%–80% B for 40 min; 80% B for 35 min; and 80%–0% B
for 5 min. Peaks were identified using deacylated 32P-standards of PI(3)P,
PI(3,4)P2, PI(3,5)P2, and PI(3,4,5)P3, and internal standards. Radioactivity
was detected by an online flow scintillation analyzer (B-RAM; LabLogic
Systems).
Apilimod/PIKfyve Truncant-Binding Assay
The Sf9 insect cells expressing PIKfyve truncants with an N-terminal His tag
were lysed in 50 mM Tris (pH 8.0), 0.3 M NaCl, 10% glycerol, 2 mM TCEP,
and 0.05% Tween, including a cocktail of protease inhibitors (cOmplete
EDTA-Free). The supernatant was filtered and loaded on a SpinTrap device
(GE Healthcare) containing NHS-activated Sepharose HP coupled to the
apilimod derivative APA10. After 30 min incubation, the resin was washed
with TBS. A first elution step was performed with 10 mM apilimod in TBS. A
second elution step was performed with 100 mM glycine buffer (pH 2.7). The
eluate was quantitatively precipitated using sodium deoxycholate and tri-
chloroacetic acid. The pellet was dissolved in 30 ml sample buffer for SDS-
PAGE and western blot.
PIKfyve Kinase Domain/Apilimod Affinity Fluorescence Polarization
Assay
Tomeasure the Cy5-apilimod/PIKfyve kinase domain-binding affinity, an equal
volume of 10 nM Cy5-apilimod and of different concentrations of PIKfyve
kinase domain proteins was incubated in 384 black microtiter plates for
90 min. After a short spin, fluorescence polarization was measured on a
PerkinElmer EnVision or a Molecular Devices Analyst GT plate reader. The
KD was determined by fitting a hyperbola using the program Prism (GraphPad
Software). Each data point was derived from n = 4 wells.
Competition by unlabeled apilimod was measured under the same condi-
tions. Its IC50was determined by fitting of a sigmoidal dose-response curve
using the Prism.
Virus Production and Infection
Lentivirus shRNA was packaged in 293T cells via cotransfection of pLP1,
pLP2, and pLP/VSVG. Retrovirus was packaged in 293T cells via cotransfec-
tion of Gag-Pol and VSVG. RAW cells were infected with supernatant contain-
ing virus plus polybrene (Sigma-Aldrich; final concentration 8 mg/ml) overnight.
The stable cell lines were maintained in medium containing puromycin
(6 mg/ml) or G418 (400 mg/ml). THP-1 cells were infected with supernatant con-
taining lentivirus plus polybrene and HEPES (final concentration 10 mM) via
spin infection (90 min, 2,100 rpm). The stable cell lines were maintained in
medium containing puromycin (2 mg/ml).
Live-Cell Imaging
For live-cell imaging, cells were seeded into a P35 glass bottom dish (MatTek)
(4 3 105 cells/dish) and maintained in phenol red-free DMEM supplemented
with 5% FBS and 25 mMHEPES (pH 7.4). Images were acquired using a Zeiss
LSM510 Meta confocal microscope with a Plan-Apochromat 633/1.4 Oil DIC
lens. Zeiss LSM Image Browser was used for imaging analysis.
Mouse Breeding
Mouse strains ingls (stock number 003095) and C57 BL/6 were purchased
from Jackson Laboratory. All mice were maintained according to NIBR animal
guidelines. The use of mice in this study is approved by Novartis Institutional
Animal Care and Use Committee as well as Office of Animal Welfare
Compliance.
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